Gram-Scale Enzymatic Synthesis of Lacto-N-fucopentaose-I, -II, and -III and Their Protective Effects Against Necrotizing Enterocolitis in Neonatal Mice

Authors:

Abstract
Human milk oligosaccharides (HMOs) are implicated in protection against necrotizing enterocolitis (NEC), yet evaluating their structure-activity relationships is hindered by the limited availability of defined fucosylated isomers. Here, we achieved gram-scale enzymatic synthesis of three lacto-N-fucopentaose isomers (LNFP-I, -II, and -III), and administered them to neonatal mice with NEC at either physiological breast-milk concentrations or equimolar doses (normalized to 2'-FL) to distinguish structural effects from concentration effects. All three LNFP isomers attenuated NEC severity through coordinated actions on inflammation, barrier integrity, epithelial proliferation, apoptosis, and gut microbiome remodeling. Notably, LNFP-I, sharing the terminal α1-2 fucose epitope with 2'-FL, showed superior suppression of intestinal IL-1β and IL-6 compared with LNFP-III (p < 0.05), while LNFP-II exhibited more pronounced effects on gut microbiota, including increased alpha diversity and reduced Escherichia-Shigella abundance. Dose-dependent effects were observed primarily for apoptosis suppression, with only equimolar doses significantly reducing cleaved caspase-3 (p < 0.05). These findings reveal that complex fucosylated HMOs, specifically the pentasaccharide LNFP isomers, confer structure-dependent functional profiles against NEC, with LNFP-I excelling in anti-inflammation and LNFP-II prevailing in microbiota modulation. This work underscores that both structural selection and dosage optimization are critical for developing effective HMO-based NEC prevention strategies.